Abstract |
Combining clinical and immunological information, a neurological syndrome can now be diagnosed as a "definite" or "possible" paraneoplastic syndrome according to the newly suggested diagnostic criteria of the PNS Euronetwork. Differentiated diagnosis of a paraneoplastic syndrome is essential for differential therapy in patients. According to the response to IVIG therapy, paraneoplastic disorders may be subgrouped in group A, a clinical response is the rule (prototype Lambert-Eaton myasthenic syndrome), and in group B, IVIG may be helpful in single patients and is indicated in specific clinical settings (prototype anti-Hu associated neurological syndromes). The mode of action of IVIG may range from direct anti-idiotype effect to indirect effects on the cellular part of the pathogenesis of paraneoplastic syndromes. Due to the therapeutic relevance, it is therefore important to diagnose a PND as early as possible, and start immunotherapy including IVIG immediately.
|
Authors | Raymond Voltz |
Journal | Journal of neurology
(J Neurol)
Vol. 253 Suppl 5
Pg. V33-8
(Sep 2006)
ISSN: 0340-5354 [Print] Germany |
PMID | 16998752
(Publication Type: Journal Article, Review)
|
Chemical References |
- Immunoglobulins, Intravenous
|
Topics |
- Humans
- Immunoglobulins, Intravenous
(therapeutic use)
- Paraneoplastic Polyneuropathy
(diagnosis, drug therapy, immunology)
|